DermFx Partners with Obagi in ALOHA Program to Test saypha MagIQ Real-World Data
Obagi Medical partners with DermFx to implement the ALOHA Program across five Southern California med spa locations, capturing standardized real-world data on saypha MagIQ’s clinical safety and efficacy. DermFx will present initial practice-based findings at internal and regional events to demonstrate the injectable’s value and patient satisfaction outcomes.
1. Partnership Details
Obagi Medical has selected DermFx as a key ALOHA Program partner, leveraging DermFx’s five Southern California med spa locations to translate FDA trial results for saypha MagIQ into routine clinical practice. DermFx’s family nurse practitioners will follow structured protocols to assess performance under everyday conditions.
2. Program Objectives
The ALOHA Program aims to generate robust real-world evidence on saypha MagIQ’s safety, gel distribution consistency, and patient satisfaction by capturing standardized data across multiple treatment sites. Structured evaluations will document usability metrics, injection force, swelling profiles and overall patient outcomes.
3. Expected Outcomes
DermFx will share initial insights at upcoming internal team meetings and regional events, highlighting the value proposition of Obagi’s injectable protocols. Positive real-world data could support broader adoption of saypha MagIQ, reinforce Obagi’s differentiated launch strategy and strengthen Waldencast’s market positioning.